Rezolute (RZLT) Research & Development (2010 - 2026)
Rezolute recorded quarterly Research & Development of $11.4 million in Q1 2026, down 20.46% quarter-over-quarter from $14.3 million in Q4 2025, and down 25.33% year-over-year from $15.3 million in Q1 2025.
Rezolute's Research & Development history runs 16 years deep, the most recent figure standing at $11.4 million for Q1 2026.
- In Q1 2026, Research & Development fell 25.33% year-over-year to $11.4 million; the TTM figure through Mar 2026 stood at $59.8 million (changed 0.03% YoY), while the FY2025 annual figure was $61.5 million, up 10.38% from the prior year.
- Research & Development came in at $11.4 million for Q1 2026 at Rezolute, down from $14.3 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $20.9 million in Q2 2025 to a low of $7.7 million in Q3 2022.
- A 5-year average of $12.8 million and a median of $12.4 million in 2024 frame the typical range for Research & Development.
- Across the five-year window, Research & Development surged 131.13% in 2022 and slipped 25.33% in 2026, its largest moves.
- Rezolute's Research & Development stood at $10.9 million in 2022, then gained by 10.0% to $12.0 million in 2023, then rose by 4.88% to $12.6 million in 2024, then rose by 13.63% to $14.3 million in 2025, then declined by 20.46% to $11.4 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $11.4 million, $14.3 million, and $13.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Rezolute | 374.41 Mn | 374.41 Mn | - | 11.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.41 Mn |
| Dec 31, 2025 | 14.35 Mn |
| Sep 30, 2025 | 13.15 Mn |
| Jun 30, 2025 | 20.86 Mn |
| Mar 31, 2025 | 15.28 Mn |
| Dec 31, 2024 | 12.63 Mn |
| Sep 30, 2024 | 12.75 Mn |
| Jun 30, 2024 | 19.09 Mn |
| Mar 31, 2024 | 12.40 Mn |
| Dec 31, 2023 | 12.04 Mn |
| Sep 30, 2023 | 12.21 Mn |
| Jun 30, 2023 | 10.93 Mn |
| Mar 31, 2023 | 14.23 Mn |
| Dec 31, 2022 | 10.95 Mn |
| Sep 30, 2022 | 7.70 Mn |
| Jun 30, 2022 | 8.57 Mn |
| Mar 31, 2022 | 8.69 Mn |
| Dec 31, 2021 | 9.45 Mn |
| Sep 30, 2021 | 5.77 Mn |
| Jun 30, 2021 | 4.39 Mn |
| Mar 31, 2021 | 3.76 Mn |
| Dec 31, 2020 | 4.50 Mn |
| Sep 30, 2020 | 2.34 Mn |
| Jun 30, 2020 | 2.45 Mn |
| Mar 31, 2020 | 3.73 Mn |
| Dec 31, 2019 | 5.04 Mn |
| Sep 30, 2019 | 3.23 Mn |
| Jun 30, 2019 | 1.72 Mn |
| Mar 31, 2019 | 15.12 Mn |
| Dec 31, 2018 | 1.31 Mn |
| Sep 30, 2018 | 930,000.00 |
| Jun 30, 2018 | 7.06 Mn |
| Mar 31, 2018 | 2.50 Mn |
| Dec 31, 2017 | 3.41 Mn |
| Sep 30, 2017 | 4.31 Mn |
| Jun 30, 2017 | 3.09 Mn |
| Mar 31, 2017 | 3.44 Mn |
| Dec 31, 2016 | 3.08 Mn |
| Sep 30, 2016 | 2.49 Mn |
| Jun 30, 2016 | 2.65 Mn |
| Mar 31, 2016 | 2.31 Mn |
| Dec 31, 2015 | 2.52 Mn |
| Sep 30, 2015 | 1.97 Mn |
| Jun 30, 2015 | 1.73 Mn |
| Mar 31, 2015 | 1.29 Mn |
| Dec 31, 2014 | 1.57 Mn |
| Sep 30, 2014 | 112,558.00 |
| Jun 30, 2014 | 32,071.00 |
| Mar 31, 2014 | 2,246.00 |
| Jun 30, 2013 | 469.00 |
| Mar 31, 2013 | 3,025.00 |
| Dec 31, 2011 | -24,500.00 |
| Sep 30, 2011 | 24,500.00 |
| Mar 31, 2011 | 23,924.00 |
| Sep 30, 2010 | 24,500.00 |